Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines

Cancer Letters

Volumn 214, Issue 2, 2004, Pages 215-224

  Gong, Soo Jung ^a   Jin, Choon Jo ^b   Rha, Sun Young ^c   Chung, Hyun Cheol ^c  

^a Eulji University School of Medicine   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Chemotherapeutics; Cytotoxicity; Gastric cancer cell line; Trastuzumab

Indexed keywords

ANTIINFECTIVE AGENT; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE S PHASE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STOMACH CANCER;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE; CISPLATIN; DOXORUBICIN; HUMANS; IMMUNOHISTOCHEMISTRY; PACLITAXEL; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 4444238149     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.04.029     Document Type: Article

References (41)

1. R.B. Dickson, and M.E. Lippman Molecular basis of breast cancer A.C. Mendelsohn A. Howley S.J. Israel L. Liotta The Molecular Basis of Cancer 1995 W.B. Saunders Philadelphia 358 384
2. M.C. Hung, and Y.K. Lau Basic science of HER-2/neu: a review Semin. Oncol. 26(4) Suppl. 12 1999 51 59
3. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
4. F. Revillion, J. Bonnatarre, and J.P. Pey ErbB-2 oncogene in human breast cancer and its clinical significance Eur. J. Cancer 34 1998 791 808
5. J.A. Kern, D.A. Schwartz, J.E. Nordberg, D.B. Weiner, M.I. Greene, K. Torney, and R.A. Robinson p185neu expression in human lung adenocarcinomas predicts shortened survival Cancer Res. 50 1990 5184 5191
6. Y. Yonemura, I. Ninomiya, A. Yamaguchi, S. Fushida, H. Kimura, and S. Ohoyama Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer Cancer Res. 51 1991 1034 1038
7. H.R. Lee, J.H. Kim, H.D. Uhm, J.B. Ahn, S.Y. Rha, and J.Y. Cho Overexpression of c-erbB-2 protein in gastric cancer by immunohistochemical stain Oncology 53 1996 192 197
8. D.J. Hetzel, T.O. Wilson, G.L. Keeney, P.C. Roche, S.S. Cha, and K.C. Podratz HER-2/neu expression: a major prognostic factor in endometrial cancer Gynecol. Oncol. 47 1992 179 185
9. R. Gorlick, A.G. Huvos, G. Heller, A. Aledo, P. Beardsley, J.H. Healey, and P.A. Meyers Expression of HER2/erbB-2 correlates with survival in osteosarcoma J. Clin. Oncol. 17 1999 2781 2788
10. S. Nicholson, C. Wright, J.R. Sainsbury, P. Halcrow, P. Kelly, B. Angus, J.R. Farndon, and A.L. Harris Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure Steroid Biochem. Mol. Biol. 37 1990 811 814
11. S. Paik, J. Bryant, C. Park, B. Fisher, E. Tan-Chiu, and D. Hyams erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer J. Natl Cancer Inst. 90 1998 361 1370
12. R.M. Hudziak, G.D. Lewis, M. Winget, B.M. Fendly, H.M. Shepard, and A. Ullrich p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor Mol. Cell Biol. 9 1989 1165 1172
13. C.L. Vogel, M.A. Cobleigh, D. Tripathy, J.C. Gutheil, L.N. Harris, and L. Fehrenbacher Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J. Clin. Oncol. 20 2002 719 726
14. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, and A. Bajamonde Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 344 2001 783 792
15. C.I. Suh, K.A. Suh, S.H. Park, H.J. Chang, J.W. Ko, and D.H. Ahn Annual report of the central cancer registry in Korea-1998 (Based on registered data from 124 hospitals) J. Korean Cancer Assoc. 32 2000 827 834
16. M.S. Karpeh, D.P. Kelsen, and J.E. Tepper Cancer of the stomach V.T. DeVita Jr. S. Hellman S.A. Rosenberg Cancer: Principles and Practice of Oncology 2001 Lippincott Philadelphia 1092 1126
17. S. Gurel, E. Dolar, O. Yerci, B. Samli, H. Ozturk, and S.G. Nak The relationship between c-erbB-2 oncogene expression and clinicopathological factors in gastric cancer J. Int. Med. Res. 27 1999 74 78
18. G.D. Lewis, I. Figari, B. Fendly, W.L. Wong, P. Carter, C. Gorman, and H.M. Shepard Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies Cancer Immunol. Immunother. 37 1993 255 263
19. H. Tsuda, S. Hirohashi, Y. Shimosato, Y. Tanaka, T. Hirota, and S. Tsugane Immunohistochemical study overexpression of c-erbB-2 protein in human breast cancer: its correlation with gene amplification and long-term survival of patients Jpn. J. Cancer Res. 81 1990 327 332
20. P.R. Twentyman, and M. Luscombe A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity Br. J. Cancer 56 1987 279 285
21. P.G. Kasprzyk, S.U. Song, P.P. Di, and C.R. King Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies Cancer Res. 52 1992 2771 2776
22. J. Baselga, D. Tripathy, J. Mendelsohn, S. Baughman, C.C. Benz, and L. Dantis Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer J. Clin. Oncol. 14 1996 737 744
23. Y. Tokuda, Y. Ohnishi, K. Shimamura, M. Iwasawa, M. Yoshimura, and Y. Ueyama In vitro and in vivo anti-tumor effects of a humanised monoclonal antibody against c-erbB-2 product Br. J. Cancer 73 1996 1362 1365
24. J. Baselga, L. Norton, J. Albanell, Y.M. Kim, and J. Mendelsohn Recombinant humanized anti-HER2 antibody(Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts Cancer Res. 58 1998 2825 2831
25. M.D. Pegram, A. Lipton, D.F. Hayes, B.L. Weber, J.M. Baselga, and D. Tripathy Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment J. Clin. Oncol. 16 1998 2659 2671
26. M. Pegram, S. Hsu, G. Lewis, R. Pietras, M. Beryt, and M. Sliwkowski Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers Oncogene 18 1999 2241 2251
27. W.N. Keith, F. Douglas, G.C. Wishart, H.M. McCallum, W.D. George, S.B. Kaye, and R. Brown Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 Eur. J. Cancer 29 1993 1469 1475
28. L.N. Harris, L. Yang, C. Tang, D. Yang, and R. Lupu Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2 Clin. Cancer Res. 4 1998 1005 1012
29. C.L. Arteaga, A.R. Winnier, M.C. Poirier, D.M. Lopez-Larraza, L.K. Shawver, S.D. Hurd, and S.J. Stewart p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair Cancer Res. 54 1994 3758 3765
30. C.M. Tsai, K.T. Chang, L. Li, R.P. Perng, and L.Y. Yang Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells Jpn. J. Cancer Res. 91 2000 213 222
31. D. Yu, B. Liu, M. Tan, J. Li, S.S. Wang, and M.C. Hung Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to taxol via mdr-1-independent mechanisms Oncogene 13 1996 1359 1365
32. J. Baselga, A.D. Seidman, P.P. Rosen, and L. Norton HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications Oncology 11 1997 43 48
33. J. Baselga, L. Norton, H. Masui, A. Pandiella, K. Coplan, W.H. Miller Jr., and J. Mendelsohn Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies J. Natl Cancer Inst. 85 1993 1327 1333
34. J. Baselga Current and planned clinical trials with trastuzumab (Herceptin) Semin. Oncol. 27 Suppl. 9 2000 27 32
35. L. Harris, G. Batist, R. Belt, D. Rovira, R. Navari, and N. Azarnia Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma Cancer 94 2002 25 36
36. J.M. Nabholtz, D.M. Reese, M.A. Lindsay, and A. Riva HER2-positive breast cancer: update on breast cancer international research group trials Clin. Breast Cancer 3 Suppl. 2 2002 75 79
37. R.J. Pietras, B.M. Fendly, V.R. Chazin, M.D. Pegram, S.D. Howell, and D.J. Slamon Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells Oncogene 9 1994 1829 1838
38. M.C. Hancock, B.C. Langton, T. Chan, P. Toy, J.J. Monahan, R.P. Mischak, and L.K. Shawver A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines Cancer Res. 51 1991 4575 4580
39. Y.F. Chang, L.L. Li, C.W. Wu, T.Y. Liu, W.Y. Lui, F.K. P'eng, and C.W. Chi Paclitaxel-induced apoptosis in human gastric carcinoma cell lines Cancer 77 1996 14 18
40. V. Kinzel, M. Kaszkin, A. Blume, and J. Richards Epidermal growth factor inhibits transiently the progression from G2-phase to mitosis: a receptor-mediated phenomenon in various cells Cancer Res. 50 1990 7932 7936
41. M.X. Sliwkowski, J.A. Lofgren, G.D. Lewis, T.E. Hotaling, B.M. Fendly, and J.A. Fox Nonclinical studies addressing the mechanism of action of trastuzumab(herceptin) Semin. Oncol. 26 1999 60 70